In NASH Race, Bad News For Conatus, Good News For Genfit In PBC
Conatus’ emricasan fails to meet the primary endpoint for portal hypertension in NASH patients with cirrhosis, but firm stresses promising subgroup data. Genfit hits Phase II primary endpoint in PBC with elafibranor, which is also in Phase III for NASH.
You may also be interested in...
After multiple Phase IIb trial failures, Conatus says it will fulfill contractual obligations and consider strategic alternatives. Partner Novartis was already focused on other candidates and partnerships in NASH.
Novartis's broad but early-stage NASH pipeline will use FXR agonist tropifexor as its keystone for developing combination therapies with outside partners.